XZXin Zhang

Xin Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xin Zhang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Wenbin Ma

    Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    2 shared publications
  • Yu Wang

    Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    2 shared publications
  • Fuping Guo

    Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100006, China

    1 shared publication
  • Hai Wang

    Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100006, China

    1 shared publication
  • Le Gong

    Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100032, PR China

    1 shared publication
  • Wenbo Wu

    Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking UnionMedical College, China Anti-Cancer Association Specialty Committee of Glioma, China

    1 shared publication

Latest Publications

  • Open Access

    Risk Prediction and Management for Central Nervous System Infection After Resection for Gliomas—The 8-Year Experience from a Tertiary Medical Center

    by Xin Zhang, Zhiyao Zheng, Xiaopeng Guo, Hai Wang, Le Gong, Yu Wang, Fuping Guo, Wenbin Ma

    Objective: To identify risk factors for central nervous system infection (CNSI) following glioma resection and develop a predictive model. Methods: Retrospective analysis of 435 glioma resection cases was conducted to assess CNSI risk factors. A nomogram predictive model was constructed and validated internally and externally. CSF characteristics and antibiotic use in CNSI patients were summarized and the impact of CNSI on long-term prognosis was evaluated. Results: CNSI incidence was 14.9%. Independent risk factors included ventricular opening, postoperative systemic infection, maximum diameter ≥ 5 cm, and preoperative peripheral blood monocyte percentage ≥ 10%. The predictive model showed good performance (C statistic = 0.797, AUC = 0.731). CNSI patients had elevated CSF protein and leukocytes, with meropenem and vancomycin as primary antibiotics. CNSI had no significant impact on long-term prognosis. Conclusions: Key risk factors for CNSI were identified, and an effective predictive model was established, providing important references for clinical decision-making and CNSI management.


  • Open Access

    Individualized Radiotherapy Timing for Postoperative Diffuse Low-Grade Glioma Patients: Managing Side Effects and Decisions

    by Xin Zhang, Wenbo Wu, Yu Wang, Xin Lian, Wenbin Ma

    This review explores the nuanced decision-making surrounding postoperative radiotherapy for diffuse low-grade glioma patients, emphasizing the need for individualized treatment to balance the benefits of tumor control with the risks of side effects. Radiotherapy is a cornerstone of diffuse low-grade glioma treatment, offering significant improvements in progression-free survival, but its potential for quality of life necessitates careful consideration of individual patient factors. The review delves into the radiotherapy timing, revealing that while early radiotherapy enhances progression-free survival, it does not significantly impact overall survival and may lead to severe and prolonged decline in long-term quality of life. Conversely, delayed radiotherapy may mitigate these side effects. The review advocates for a patient-centered approach, emphasizing the importance of weighing individual risks and benefits, and highlights the potential of artificial intelligence in predicting quality of life and the need to revisit previous research findings in light of the 2021 WHO (World Health Organization) classification update, underscoring the evolving nature of low-grade glioma treatment and the ongoing quest for optimal therapeutic strategies.